International expert joins SUDA Pharmaceuticals’ (ASX:SUD) scientific advisory board
SUDA Pharmaceuticals (SUD) appoints Reuben Benjamin to its scientific advisory board for…
Suda Pharmaceuticals Ltd (SUD:ASX)
5.2¢
0 (0%)
MCAP $25.00M
Last trade
15.35pm 17/09/2021
20mins delayed
Latest Announcements
15/09/2021SUDSuda Pharmaceuticals Ltd
07/09/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
5,166
MCap
03/09/2021SUDSuda Pharmaceuticals Ltd
31/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
315
MCap
26/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
24/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
23/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
3,160
MCap
16/08/2021 Price SensitivePSSUDSuda Pharmaceuticals Ltd
786
MCap
Company Overview
SUDA Pharmaceuticals Limited is a biotechnology company focused on developing therapies to treat human disease. The Company is focused on two areas which include oncology and conditions that impact the central nervous system. The Company is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The Company’s OroMist technology develop oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. It is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
